Invivyd (IVVD) Capital Expenditures (2021 - 2025)
Invivyd's (IVVD) quarterly Capital Expenditures came in at $11000.0 in Q2 2025, up 114.47% on a YoY basis from $5128.8 in Q2 2024, and down 92.36% quarter-over-quarter from $144000.0 in Q1 2025.
Analysis
Invivyd (IVVD) Capital Expenditures (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Capital Expenditures for 5 consecutive years, with $11000.0 the latest figure, recorded in Q2 2025.
- For the quarter ending Q2 2025, Capital Expenditures rose 114.47% year-over-year to $11000.0; the trailing twelve-month figure through Dec 2025 stood at $155000.0 (up 209.93% YoY), and the FY2025 full-year result was $155000.0, up 209.93% from the prior year.
- Capital Expenditures slipped to $11000.0 in Q2 2025 per IVVD's latest filing, from $144000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $6.0 million in Q3 2021 and bottomed at -$7.4 million in Q4 2024.
- Historically, Capital Expenditures has averaged $58571.4 across 5 years, with a median of $1000.0 in 2023.
- The widest YoY moves for Capital Expenditures: up 169.55% in 2024, down 744.44% in 2024.
- Over 5 years, Capital Expenditures stood at -$2.7 million in 2021, then surged by 98.34% to -$45000.0 in 2022, then surged by 80.0% to -$9000.0 in 2023, then slumped by 82322.22% to -$7.4 million in 2024, then soared by 100.15% to $11000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $11000.0, $144000.0, and -$7.4 million for Q2 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 144,000.00 |
| Dec 31, 2024 | -7.42 Mn |
| Sep 30, 2024 | 5.67 Mn |
| Jun 30, 2024 | -76,000.00 |
| Mar 31, 2024 | 1.68 Mn |
| Jun 30, 2023 | -9,000.00 |
| Mar 31, 2023 | 624,000.00 |
| Dec 31, 2022 | -45,000.00 |
| Sep 30, 2022 | -63,000.00 |
| Jun 30, 2022 | 62,000.00 |
| Mar 31, 2022 | -3.06 Mn |
| Dec 31, 2021 | -2.72 Mn |
| Sep 30, 2021 | 6.02 Mn |